Rafarma Pharmaceuticals Stock Probability of Future Pink Sheet Price Finishing Under 0.092

RAFA Stock  USD 0.10  0.02  29.87%   
Rafarma Pharmaceuticals' future price is the expected price of Rafarma Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Rafarma Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Rafarma Pharmaceuticals Backtesting, Rafarma Pharmaceuticals Valuation, Rafarma Pharmaceuticals Correlation, Rafarma Pharmaceuticals Hype Analysis, Rafarma Pharmaceuticals Volatility, Rafarma Pharmaceuticals History as well as Rafarma Pharmaceuticals Performance.
  
Please specify Rafarma Pharmaceuticals' target price for which you would like Rafarma Pharmaceuticals odds to be computed.

Rafarma Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rafarma Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rafarma Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Rafarma Pharmaceuticals is way too risky over 90 days horizon
Rafarma Pharmaceuticals has some characteristics of a very speculative penny stock
Rafarma Pharmaceuticals appears to be risky and price may revert if volatility continues
Rafarma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (14.85 K) with profit before overhead, payroll, taxes, and interest of 0.
Rafarma Pharmaceuticals generates negative cash flow from operations

Rafarma Pharmaceuticals Technical Analysis

Rafarma Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Rafarma Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Rafarma Pharmaceuticals. In general, you should focus on analyzing Rafarma Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Rafarma Pharmaceuticals Predictive Forecast Models

Rafarma Pharmaceuticals' time-series forecasting models is one of many Rafarma Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Rafarma Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Rafarma Pharmaceuticals

Checking the ongoing alerts about Rafarma Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Rafarma Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Rafarma Pharmaceuticals is way too risky over 90 days horizon
Rafarma Pharmaceuticals has some characteristics of a very speculative penny stock
Rafarma Pharmaceuticals appears to be risky and price may revert if volatility continues
Rafarma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (14.85 K) with profit before overhead, payroll, taxes, and interest of 0.
Rafarma Pharmaceuticals generates negative cash flow from operations

Other Information on Investing in Rafarma Pink Sheet

Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.